Baclofen is a y-aminobutyric acid agonist that has been licenced for the treatment of spasticity and is widely used in the treatment of neuropathic pain. This medicine has been shown to be effective in the treatment of trigeminal neuralgia in controlled investigations. Baclofen is a gamma-aminobutyric acid agonist that has been approved for the treatment of spasticity and is commonly used in the treatment of neuropathic pain. In controlled studies, this drug has been demonstrated to be effective in the treatment of trigeminal neuralgia. The most effective use of bachfen as an adjuvant analgesic necessitates a thorough understanding of its pharmacology, side effect profile, and dose guidelines, all of which have proven to be valuable in clinical practise [1]. While baclofen was developed as a more brain penetrant form of GABA (-aminobutyric acid) for the treatment of epilepsy, its highly effective muscle relaxant qualities led to its approval as a race mate for the treatment of spasticity. Baclofen was approved by the FDA before its receptor, GABAB, was discovered and its full mechanism of action was understood.
PDFShare this article
Journal of Anesthesiology and Pain Research received 835 citations as per Google Scholar report
